Last updated: February 19, 2026
Combipatch, a transdermal hormone therapy combining estradiol and norethindrone acetate, is supplied primarily by pharmaceutical manufacturers specializing in hormone replacement therapy (HRT) formulations.
Major Suppliers and Manufacturers
| Company |
Product Name |
Market Status |
Manufacturing Details |
| Mylan (now part of Viatris) |
Combipatch (Estradiol/Norethindrone) |
Approved in multiple countries |
Licensed production of Combipatch; historically among the largest suppliers. |
| Noven Therapeutics |
Estradiol/Norethindrone transdermal patch |
Marketed primarily in the U.S. |
Develops and produces hormone transdermal patches, including Combipatch. |
| Novo Nordisk |
No direct Combipatch product |
Does not produce Combipatch; another hormone supplier |
Competitor in HRT segments but not a Combipatch supplier. |
Manufacturing and Licensing
- Mylan / Viatris holds the original patent and manufacturing rights for Combipatch, with production licenses granted to third-party manufacturers in select regions.
- Noven Therapeutics produces a similar combination hormone patch and may supply through licensing agreements or direct sales, depending on regulatory approval.
Supply Chain Considerations
- Geographic Availability: Combipatch is mainly available in the U.S., with limited distribution elsewhere due to regulatory differences.
- Regulatory Status: Approved by the FDA for hormone therapy; export and supply depend on country-specific regulatory approvals.
- Production Capacity: Limited to manufacturing facilities with specialized transdermal patch capabilities, which are few in number.
Market and Contract Trends
- The market for hormone patches faces competition from oral pills and other delivery systems.
- Supply chain disruptions have occasionally affected availability, notably during the COVID-19 pandemic.
- Contract manufacturing may involve third-party facilities in Europe and North America with Good Manufacturing Practice (GMP) certification.
Key Suppliers Summary
- Viatris (formerly Mylan): Primary legal supplier and distributor.
- Noven Therapeutics: Produces similar hormone patches, potentially as an alternative supplier.
- Other Manufacturers: Limited presence; some may supply through licensing agreements or regional partnerships.
Regulatory and Patent Outlook
- Mylan held patents associated with Combipatch until their expiration, after which generic or biosimilar alternatives could enter the market.
- Regulatory pathways for biosimilars or generics are ongoing in various jurisdictions, potentially altering supply dynamics.
Final Notes
Supply for Combipatch remains concentrated among limited manufacturers due to the technical complexity of transdermal hormone delivery. Most supply is within North American markets via licensed manufacturers, with regulatory and patent landscapes dictating future supply options.
Key Takeaways
- Major suppliers include Viatris (Mylan) and Noven Therapeutics.
- Production is limited to specialized GMP-certified facilities.
- Market availability mainly restricted to North America.
- Patent expirations may lead to increased generic competition.
- Supply disruptions can occur due to manufacturing or regulatory issues.
FAQs
1. Who are the primary manufacturers of Combipatch?
Viatris (formerly Mylan) and Noven Therapeutics are the main suppliers, with license agreements enabling manufacturing and distribution.
2. Is Combipatch available outside the United States?
Availability outside the U.S. depends on regional regulatory approvals; it is primarily marketed within North America.
3. Are there generic versions of Combipatch?
Patent expirations may lead to generics, but as of now, no approved generic versions are widely available.
4. How does supply chain disruption impact Combipatch availability?
Disruptions can lead to shortages, especially during manufacturing delays or regulatory approvals, as seen during the COVID-19 pandemic.
5. Can other companies produce similar hormone patches?
Yes, companies like Noven produce similar hormone transdermal patches, but they may not supply Combipatch specifically.
References
- U.S. Food and Drug Administration. (2023). Combipatch approval details. https://www.fda.gov
- Mylan. (2022). Product portfolio. https://www.viatris.com
- Noven Therapeutics. (2022). Company overview. https://www.noven.com
- European Medicines Agency. (2023). Hormone therapy approvals. https://www.ema.europa.eu
